Performance of 18F-FDG PET vs. Conventional Imaging Modalities Among Restaging Patient Group (n = 20)
| Patient | State | Pathology | CI | PET | Incongruence | PET impact on management |
|---|---|---|---|---|---|---|
| 1–2 | CR | SCLC | RD | CR | False-positive mediastinal lymph nodes (CT) | Chemotherapy cessation |
| 3–5 | CR | SCLC | CR | CR | — | — |
| 6 | RD | SCLC | RD | CR | False-negative subcarinal lymph node (PET) | — |
| 7 | RD | SCLC | CR | RD | Active parenchymal lung lesion (PET) | Chemotherapy reinstitution |
| 8 | RD | SCLC | RD | RD | False-positive sternal metastasis (CT, BS) | — |
| 9 | RD | SCLC | RD | RD | True-positive soft-tissue metastases (PET) | — |
| 10–17 | RD | SCLC | RD | RD | — | — |
| 18–20 | PD | SCLC | PD | PD | — | — |
CI = conventional imaging modalities; RD = residual disease; CR = complete response; BS = bone scan; PD = progressive disease.